These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36625973)

  • 41. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
    Gonzalez-Duarte A
    Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autonomic dysfunction in cancer cachexia coincides with large fiber polyneuropathy.
    Hundsberger T; Omlin A; Haegele-Link S; Vehoff J; Strasser F
    J Pain Symptom Manage; 2014 Oct; 48(4):611-8.e1. PubMed ID: 24709363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy.
    Chiang MC; Yeh TY; Sung JY; Hsueh HW; Kao YH; Hsueh SJ; Chang KC; Feng FP; Lin YH; Chao CC; Hsieh ST
    Eur J Neurol; 2021 Mar; 28(3):982-991. PubMed ID: 33369810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
    Adams D; Algalarrondo V; Polydefkis M; Sarswat N; Slama MS; Nativi-Nicolau J
    Orphanet J Rare Dis; 2021 Oct; 16(1):411. PubMed ID: 34602081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects.
    Luigetti M; Guglielmino V; Romozzi M; Romano A; Di Paolantonio A; Bisogni G; Sabatelli E; Modoni A; Sabatelli M; Servidei S; Lo Monaco M
    Brain Sci; 2022 Aug; 12(8):. PubMed ID: 36009100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Motor Conduction Studies and Handgrip in Hereditary TTR Amyloidosis: Simple Tools to Evaluate the Upper Limbs.
    Di Stefano V; Thomas E; Giustino V; Iacono S; Torrente A; Pillitteri G; Gagliardo A; Lupica A; Palma A; Battaglia G; Brighina F
    Front Neurol; 2022; 13():835812. PubMed ID: 35295833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Valsalva manoeuvre in patients with different Parkinsonian disorders.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Reichmann H; Berg D; Ziemssen T
    J Neural Transm (Vienna); 2009 Jul; 116(7):875-80. PubMed ID: 19499177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.
    Masuda T; Misumi Y; Nomura T; Yamakawa S; Tasaki M; Obayashi K; Ando Y; Ueda M
    Muscle Nerve; 2024 Jan; 69(1):99-102. PubMed ID: 37960924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
    Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
    BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
    Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
    ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength.
    Di Stefano V; Thomas E; Alonge P; Giustino V; Pillitteri G; Leale I; Torrente A; Pignolo A; Norata D; Iacono S; Lupica A; Palma A; Battaglia G; Brighina F
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
    Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
    J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative sensory testing and skin biopsy findings in late-onset ATTRv presymptomatic carriers: Relationships with predicted time of disease onset (PADO).
    Leonardi L; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Lauletta A; Rossini E; Tufano L; Ceccanti M; Esposito N; Falco P; di Pietro G; Truini A; Galosi E
    J Peripher Nerv Syst; 2023 Sep; 28(3):390-397. PubMed ID: 37535421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. INvesTigating the Abnormality of detrusor ConTractility by uroflowmetry in diabetic children (INTACT Trial): protocol of a prospective, observational study.
    Martonosi ÁR; Pázmány P; Kiss S; Zsákai A; Szabó L
    BMJ Open; 2022 Nov; 12(11):e062198. PubMed ID: 36375985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.